{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:46:34Z","timestamp":1794271594173,"version":"4.9.0"},"reference-count":246,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Research Grant Committee of Hong Kong","award":["17119621, 17111424, 17120225"],"award-info":[{"award-number":["17119621, 17111424, 17120225"]}]},{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"crossref","award":["21222151, 19201591 and 15162961"],"award-info":[{"award-number":["21222151, 19201591 and 15162961"]}],"id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010428","name":"Innovation and Technology Fund","doi-asserted-by":"crossref","award":["PRP\/028\/22FX & PRP\/029\/24FX"],"award-info":[{"award-number":["PRP\/028\/22FX & PRP\/029\/24FX"]}],"id":[{"id":"10.13039\/501100010428","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Young Qihuang Scholar of the \"Tens of Millions\" Talent Project of China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02707-5","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:04:51Z","timestamp":1780545891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Histone modifications across cancers: mechanisms, therapy and clinical translation"],"prefix":"10.1186","volume":"25","author":[{"given":"Pengde","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yau-Tuen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Fung","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiucheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuofeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqing","family":"Xun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Leong","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ming","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"3","key":"2707_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2707_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13045-024-01640-8","volume":"17","author":"Z Wu","year":"2024","unstructured":"Wu Z, Xia F, Lin R. Global burden of cancer and associated risk factors in 204 countries and territories, 1980\u20132021: a systematic analysis for the GBD 2021. J Hematol Oncol. 2024;17(1):119.","journal-title":"J Hematol Oncol"},{"issue":"10512","key":"2707_CR3","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/S0140-6736(25)01570-3","volume":"406","author":"Q Luo","year":"2025","unstructured":"Luo Q, Smith DP. Global cancer burden: progress, projections, and challenges. Lancet. 2025;406(10512):1536\u20137.","journal-title":"Lancet"},{"key":"2707_CR4","doi-asserted-by":"crossref","unstructured":"Siegel RL et al. Cancer statistics, 2025. CA: A Cancer Journal for Clinicians, 2025. 75(1): pp. 10\u201345.","DOI":"10.3322\/caac.21871"},{"key":"2707_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejca.2022.08.015","volume":"175","author":"J Hemminki","year":"2022","unstructured":"Hemminki J, et al. Survival trends in solid cancers in the Nordic countries through 50 years. Eur J Cancer. 2022;175:77\u201385.","journal-title":"Eur J Cancer"},{"key":"2707_CR6","doi-asserted-by":"crossref","unstructured":"Kim J et al. A 5-Year Mortality Prediction Model for Prostate Cancer Patients Based on the Korean Nationwide Health Insurance Claims Database. J Pers Med, 2024. 14(10).","DOI":"10.3390\/jpm14101058"},{"issue":"12","key":"2707_CR7","doi-asserted-by":"publisher","first-page":"15409","DOI":"10.3390\/ijerph121214993","volume":"12","author":"Z Wang","year":"2015","unstructured":"Wang Z, et al. Secular Trends of Breast Cancer in China, South Korea, Japan and the United States: Application of the Age-Period-Cohort Analysis. Int J Environ Res Public Health. 2015;12(12):15409\u201318.","journal-title":"Int J Environ Res Public Health"},{"key":"2707_CR8","doi-asserted-by":"publisher","first-page":"891652","DOI":"10.3389\/fonc.2022.891652","volume":"12","author":"TB Emran","year":"2022","unstructured":"Emran TB, et al. Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches. Front Oncol. 2022;12:891652.","journal-title":"Front Oncol"},{"issue":"3","key":"2707_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1267\/ahc.23-00014","volume":"56","author":"R Kitazawa","year":"2023","unstructured":"Kitazawa R, Haraguchi R, Kitazawa S. Histone Modification in Histochemistry and Cytochemistry. Acta Histochem Cytochem. 2023;56(3):41\u20137.","journal-title":"Acta Histochem Cytochem"},{"issue":"1","key":"2707_CR10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41392-024-01918-w","volume":"9","author":"W Yao","year":"2024","unstructured":"Yao W, Hu X, Wang X. Crossing epigenetic frontiers: the intersection of novel histone modifications and diseases. Signal Transduct Target Ther. 2024;9(1):232.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2707_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","volume":"22","author":"KH Kim","year":"2016","unstructured":"Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med. 2016;22(2):128\u201334.","journal-title":"Nat Med"},{"issue":"7","key":"2707_CR12","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s12276-022-00812-1","volume":"54","author":"J Kim","year":"2022","unstructured":"Kim J, et al. Gene regulation by histone-modifying enzymes under hypoxic conditions: a focus on histone methylation and acetylation. Exp Mol Med. 2022;54(7):878\u201389.","journal-title":"Exp Mol Med"},{"issue":"1","key":"2707_CR13","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.1038\/s41467-024-50882-0","volume":"15","author":"FE Machour","year":"2024","unstructured":"Machour FE, et al. Harnessing DNA replication stress to target RBM10 deficiency in lung adenocarcinoma. Nat Commun. 2024;15(1):6417.","journal-title":"Nat Commun"},{"key":"2707_CR14","doi-asserted-by":"publisher","first-page":"114313","DOI":"10.1016\/j.biopha.2023.114313","volume":"160","author":"M Entezari","year":"2023","unstructured":"Entezari M, et al. The pharmacological and biological importance of EZH2 signaling in lung cancer. Biomed Pharmacother. 2023;160:114313.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"2707_CR15","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1097\/PAI.0000000000001055","volume":"30","author":"Y Gan","year":"2022","unstructured":"Gan Y, et al. EZH2 Protein Expression in Estrogen Receptor Positive Invasive Breast Cancer Treated With Neoadjuvant Endocrine Therapy: An Exploratory Study of Association With Tumor Response. Appl Immunohistochem Mol Morphol. 2022;30(9):614\u201322.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"4","key":"2707_CR16","first-page":"277","volume":"2","author":"Y Yang","year":"2022","unstructured":"Yang Y, Zhang M, Wang Y. The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy. J Natl Cancer Cent. 2022;2(4):277\u201390.","journal-title":"J Natl Cancer Cent"},{"key":"2707_CR17","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.3389\/freae.2025.1723159","volume":"3","author":"H Sultana","year":"2025","unstructured":"Sultana H, et al. Epigenetic dysregulation in pancreatic cancer: emerging biomarkers and clinical applications. Front Epigenetics Epigenomics. 2025;3:2025.","journal-title":"Front Epigenetics Epigenomics"},{"issue":"37","key":"2707_CR18","doi-asserted-by":"publisher","first-page":"22612","DOI":"10.1074\/jbc.M115.661363","volume":"290","author":"M Brehove","year":"2015","unstructured":"Brehove M, et al. Histone Core Phosphorylation Regulates DNA Accessibility*. J Biol Chem. 2015;290(37):22612\u201321.","journal-title":"J Biol Chem"},{"issue":"1","key":"2707_CR19","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41467-018-03895-5","volume":"9","author":"F Wojcik","year":"2018","unstructured":"Wojcik F, et al. Functional crosstalk between histone H2B ubiquitylation and H2A modifications and variants. Nat Commun. 2018;9(1):1394.","journal-title":"Nat Commun"},{"issue":"4","key":"2707_CR20","doi-asserted-by":"publisher","first-page":"a019521","DOI":"10.1101\/cshperspect.a019521","volume":"8","author":"JE Audia","year":"2016","unstructured":"Audia JE, Campbell RM. Histone Modifications and Cancer. Cold Spring Harb Perspect Biol. 2016;8(4):a019521.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2707_CR21","doi-asserted-by":"publisher","first-page":"1495221","DOI":"10.3389\/fimmu.2024.1495221","volume":"15","author":"X Duan","year":"2024","unstructured":"Duan X, et al. The role of histone post-translational modifications in cancer and cancer immunity: functions, mechanisms and therapeutic implications. Front Immunol. 2024;15:1495221.","journal-title":"Front Immunol"},{"issue":"1","key":"2707_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13148-020-00941-2","volume":"12","author":"D Komar","year":"2020","unstructured":"Komar D, Juszczynski P. Rebelled epigenome: histone H3S10 phosphorylation and H3S10 kinases in cancer biology and therapy. Clin Epigenetics. 2020;12(1):147.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"2707_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1101\/gr.224717.117","volume":"28","author":"CCL Chen","year":"2018","unstructured":"Chen CCL, et al. H3S10ph broadly marks early-replicating domains in interphase ESCs and shows reciprocal antagonism with H3K9me2. Genome Res. 2018;28(1):37\u201351.","journal-title":"Genome Res"},{"key":"2707_CR24","doi-asserted-by":"crossref","unstructured":"Oss-Ronen L, Sarusi T, Cohen I. Histone Mono-Ubiquitination in Transcriptional Regulation and Its Mark on Life: Emerging Roles in Tissue Development and Disease. Cells, 2022. 11(15).","DOI":"10.3390\/cells11152404"},{"key":"2707_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.dnarep.2017.06.011","volume":"56","author":"M Uckelmann","year":"2017","unstructured":"Uckelmann M, Sixma TK. Histone ubiquitination in the DNA damage response. DNA Repair. 2017;56:92\u2013101.","journal-title":"DNA Repair"},{"issue":"7","key":"2707_CR26","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1016\/j.celrep.2016.04.041","volume":"15","author":"S Ramachandran","year":"2016","unstructured":"Ramachandran S, et al. The SAGA Deubiquitination Module Promotes DNA Repair and Class Switch Recombination through ATM and DNAPK-Mediated \u03b3H2AX Formation. Cell Rep. 2016;15(7):1554\u201365.","journal-title":"Cell Rep"},{"key":"2707_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2014.00155","volume":"5","author":"V Dehennaut","year":"2014","unstructured":"Dehennaut V, Leprince D, Lefebvre T. O-GlcNAcylation, an Epigenetic Mark. Focus on the Histone Code, TET Family Proteins, and Polycomb Group Proteins. Front Endocrinol (Lausanne). 2014;5:155.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"2707_CR28","doi-asserted-by":"publisher","first-page":"5594","DOI":"10.1093\/nar\/gku236","volume":"42","author":"Q Xu","year":"2014","unstructured":"Xu Q, et al. AMPK regulates histone H2B O-GlcNAcylation. Nucleic Acids Res. 2014;42(9):5594\u2013604.","journal-title":"Nucleic Acids Res"},{"issue":"15","key":"2707_CR29","doi-asserted-by":"publisher","first-page":"12195","DOI":"10.1074\/jbc.M111.315804","volume":"287","author":"JJ Fong","year":"2012","unstructured":"Fong JJ, et al. \u03b2-N-Acetylglucosamine (O-GlcNAc) Is a Novel Regulator of Mitosis-specific Phosphorylations on Histone H3*. J Biol Chem. 2012;287(15):12195\u2013203.","journal-title":"J Biol Chem"},{"issue":"3","key":"2707_CR30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10863-018-9742-3","volume":"50","author":"ZA Bacigalupa","year":"2018","unstructured":"Bacigalupa ZA, Bhadiadra CH, Reginato MJ. O-GlcNAcylation: key regulator of glycolytic pathways. J Bioenerg Biomembr. 2018;50(3):189\u201398.","journal-title":"J Bioenerg Biomembr"},{"issue":"23","key":"2707_CR31","doi-asserted-by":"publisher","first-page":"13225","DOI":"10.1073\/pnas.1735528100","volume":"100","author":"Y Shiio","year":"2003","unstructured":"Shiio Y, Eisenman RN. Histone sumoylation is associated with transcriptional repression. Proc Natl Acad Sci U S A. 2003;100(23):13225\u201330.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2707_CR32","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1093\/nar\/gkab280","volume":"49","author":"HY Ryu","year":"2021","unstructured":"Ryu HY, Hochstrasser M. Histone sumoylation and chromatin dynamics. Nucleic Acids Res. 2021;49(11):6043\u201352.","journal-title":"Nucleic Acids Res"},{"issue":"49","key":"2707_CR33","doi-asserted-by":"publisher","first-page":"33827","DOI":"10.1074\/jbc.M114.591644","volume":"289","author":"A Dhall","year":"2014","unstructured":"Dhall A, et al. Sumoylated human histone H4 prevents chromatin compaction by inhibiting long-range internucleosomal interactions. J Biol Chem. 2014;289(49):33827\u201337.","journal-title":"J Biol Chem"},{"issue":"1","key":"2707_CR34","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1038\/s41467-025-58925-w","volume":"16","author":"D-W Jeong","year":"2025","unstructured":"Jeong D-W, et al. Auto-sumoylation of the yeast Ubc9 E2 SUMO-conjugating enzyme extends cellular lifespan. Nat Commun. 2025;16(1):3735.","journal-title":"Nat Commun"},{"key":"2707_CR35","doi-asserted-by":"publisher","first-page":"103711","DOI":"10.1016\/j.dnarep.2024.103711","volume":"140","author":"C \u00d6zdemir","year":"2024","unstructured":"\u00d6zdemir C, et al. PARticular MARks: Histone ADP-ribosylation and the DNA damage response. DNA Repair (Amst). 2024;140:103711.","journal-title":"DNA Repair (Amst)"},{"key":"2707_CR36","doi-asserted-by":"publisher","first-page":"118202","DOI":"10.1016\/j.bmc.2025.118202","volume":"125","author":"Y Wu","year":"2025","unstructured":"Wu Y, Tang L, Liu Q. Recent advances in the synthesis of poly (ADP-ribose). Bioorg Med Chem. 2025;125:118202.","journal-title":"Bioorg Med Chem"},{"key":"2707_CR37","doi-asserted-by":"crossref","unstructured":"Harrision D et al. Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) \u2013 Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy. Front Mol Biosci, 2020. Volume 7\u20132020.","DOI":"10.3389\/fmolb.2020.00191"},{"issue":"7","key":"2707_CR38","doi-asserted-by":"publisher","first-page":"114433","DOI":"10.1016\/j.celrep.2024.114433","volume":"43","author":"HA Anagho","year":"2024","unstructured":"Anagho HA, et al. ADP-ribosylome analysis reveals homogeneous DNA-damage-induced serine ADP-ribosylation across wild-type and BRCA-mutant breast cancer cell lines. Cell Rep. 2024;43(7):114433.","journal-title":"Cell Rep"},{"issue":"2","key":"2707_CR39","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41580-025-00876-7","volume":"27","author":"X Sheng","year":"2026","unstructured":"Sheng X, et al. Biochemistry and regulation of histone lysine L-lactylation. Nat Rev Mol Cell Biol. 2026;27(2):95\u2013109.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"2707_CR40","doi-asserted-by":"publisher","first-page":"e70499","DOI":"10.1002\/ctm2.70499","volume":"15","author":"H Guo","year":"2025","unstructured":"Guo H, et al. Exploring the mechanisms of mutual influence between lactylation and macrophage polarization in the context of disease. Clin Transl Med. 2025;15(11):e70499.","journal-title":"Clin Transl Med"},{"key":"2707_CR41","doi-asserted-by":"publisher","first-page":"101248","DOI":"10.1016\/j.drup.2025.101248","volume":"81","author":"Y Sun","year":"2025","unstructured":"Sun Y, et al. Lactylation in cancer progression and drug resistance. Drug Resist Updates. 2025;81:101248.","journal-title":"Drug Resist Updates"},{"issue":"1","key":"2707_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13059-021-02308-z","volume":"22","author":"J Yu","year":"2021","unstructured":"Yu J, et al. Histone lactylation drives oncogenesis by facilitating m6A reader protein YTHDF2 expression in ocular melanoma. Genome Biol. 2021;22(1):85.","journal-title":"Genome Biol"},{"issue":"21","key":"2707_CR43","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1158\/0008-5472.CAN-23-3513","volume":"84","author":"C Zhang","year":"2024","unstructured":"Zhang C, et al. H3K18 Lactylation Potentiates Immune Escape of Non-Small Cell Lung Cancer. Cancer Res. 2024;84(21):3589\u2013601.","journal-title":"Cancer Res"},{"issue":"1","key":"2707_CR44","doi-asserted-by":"publisher","first-page":"6588","DOI":"10.1038\/s41467-025-61474-x","volume":"16","author":"Q Xu","year":"2025","unstructured":"Xu Q, et al. Regulation of plant immunity through histone H3 \u03b2-hydroxybutyrylation-mediated transcriptional control. Nat Commun. 2025;16(1):6588.","journal-title":"Nat Commun"},{"issue":"1","key":"2707_CR45","first-page":"8805868","volume":"2024","author":"R Rezaei","year":"2024","unstructured":"Rezaei R, et al. Exploring the Therapeutic Potential of \u03b2-Hydroxybutyrate (BHB) in Clear Cell Renal Cell Carcinoma: A Journey into Fat Browning, Autophagy, and Tumor Slimming. Int J Clin Pract. 2024;2024(1):8805868.","journal-title":"Int J Clin Pract"},{"issue":"1","key":"2707_CR46","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41420-024-01830-w","volume":"10","author":"J-y Xie","year":"2024","unstructured":"Xie J-y, et al. The mechanisms, regulations, and functions of histone lysine crotonylation. Cell Death Discovery. 2024;10(1):66.","journal-title":"Cell Death Discovery"},{"issue":"1","key":"2707_CR47","doi-asserted-by":"publisher","first-page":"14690","DOI":"10.1038\/s41598-018-32927-9","volume":"8","author":"RDW Kelly","year":"2018","unstructured":"Kelly RDW, et al. Histone deacetylase (HDAC) 1 and 2 complexes regulate both histone acetylation and crotonylation in vivo. Sci Rep. 2018;8(1):14690.","journal-title":"Sci Rep"},{"issue":"7","key":"2707_CR48","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41419-021-03987-z","volume":"12","author":"G Jiang","year":"2021","unstructured":"Jiang G, et al. Protein lysine crotonylation: past, present, perspective. Cell Death Dis. 2021;12(7):703.","journal-title":"Cell Death Dis"},{"issue":"8","key":"2707_CR49","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41419-022-05165-1","volume":"13","author":"D Zhang","year":"2022","unstructured":"Zhang D, et al. Global crotonylome reveals hypoxia-mediated lamin A crotonylation regulated by HDAC6 in liver cancer. Cell Death Dis. 2022;13(8):717.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2707_CR50","doi-asserted-by":"publisher","first-page":"6915","DOI":"10.1038\/s41467-024-51232-w","volume":"15","author":"Z Guo","year":"2024","unstructured":"Guo Z, et al. Hypoxia-induced downregulation of PGK1 crotonylation promotes tumorigenesis by coordinating glycolysis and the TCA cycle. Nat Commun. 2024;15(1):6915.","journal-title":"Nat Commun"},{"key":"2707_CR51","doi-asserted-by":"publisher","first-page":"148586","DOI":"10.1016\/j.ijbiomac.2025.148586","volume":"332","author":"F Bashir","year":"2025","unstructured":"Bashir F, et al. Structural and mechanistic insights into peptidylarginine deiminase (PAD2\/PAD4) mediated citrullination and therapeutic targeting: A review. Int J Biol Macromol. 2025;332:148586.","journal-title":"Int J Biol Macromol"},{"issue":"5","key":"2707_CR52","doi-asserted-by":"publisher","first-page":"107602","DOI":"10.1016\/j.celrep.2020.107602","volume":"31","author":"T-D Tsourouktsoglou","year":"2020","unstructured":"Tsourouktsoglou T-D, et al. Histones, DNA, and Citrullination Promote Neutrophil Extracellular Trap Inflammation by Regulating the Localization and Activation of TLR4. Cell Rep. 2020;31(5):107602.","journal-title":"Cell Rep"},{"key":"2707_CR53","doi-asserted-by":"crossref","unstructured":"Zhu D et al. PAD4 and Its Inhibitors in Cancer Progression and Prognosis. Pharmaceutics, 2022. 14(11).","DOI":"10.3390\/pharmaceutics14112414"},{"key":"2707_CR54","doi-asserted-by":"crossref","unstructured":"Liu K et al. 5-HT orchestrates histone serotonylation and citrullination to drive neutrophil extracellular traps and liver metastasis. J Clin Investig, 2025. 135(8).","DOI":"10.1172\/JCI183544"},{"issue":"1","key":"2707_CR55","doi-asserted-by":"publisher","first-page":"5393","DOI":"10.1038\/s41467-025-61029-0","volume":"16","author":"L Love","year":"2025","unstructured":"Love L, et al. PADI4-mediated citrullination of histone H3 stimulates HIV-1 transcription. Nat Commun. 2025;16(1):5393.","journal-title":"Nat Commun"},{"issue":"1","key":"2707_CR56","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13(1):104.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2707_CR57","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.molcel.2013.01.038","volume":"49","author":"E Calo","year":"2013","unstructured":"Calo E, Wysocka J. Modification of enhancer chromatin: what, how, and why? Mol Cell. 2013;49(5):825\u201337.","journal-title":"Mol Cell"},{"issue":"1","key":"2707_CR58","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s43556-022-00070-7","volume":"3","author":"H Ruan","year":"2022","unstructured":"Ruan H, et al. Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer. Mol Biomed. 2022;3(1):10.","journal-title":"Mol Biomed"},{"key":"2707_CR59","doi-asserted-by":"publisher","first-page":"e36696","DOI":"10.7554\/eLife.36696","volume":"7","author":"D Fang","year":"2018","unstructured":"Fang D, et al. H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers. eLife. 2018;7:e36696.","journal-title":"eLife"},{"key":"2707_CR60","doi-asserted-by":"publisher","first-page":"1044585","DOI":"10.3389\/fmmed.2022.1044585","volume":"2","author":"Y Hao","year":"2022","unstructured":"Hao Y, et al. Acetyl-CoA: An interplay between metabolism and epigenetics in cancer. Front Mol Med. 2022;2:1044585.","journal-title":"Front Mol Med"},{"issue":"11","key":"2707_CR61","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1016\/j.celrep.2017.11.038","volume":"21","author":"S Das","year":"2017","unstructured":"Das S, et al. Citrate Lyase Regulates Myofiber Differentiation and Increases Regeneration by Altering Histone Acetylation. Cell Rep. 2017;21(11):3003\u201311.","journal-title":"Cell Rep"},{"issue":"1","key":"2707_CR62","doi-asserted-by":"publisher","first-page":"188837","DOI":"10.1016\/j.bbcan.2022.188837","volume":"1878","author":"W He","year":"2023","unstructured":"He W, Li Q, Li X. Acetyl-CoA regulates lipid metabolism and histone acetylation modification in cancer. Biochim et Biophys Acta (BBA) - Reviews Cancer. 2023;1878(1):188837.","journal-title":"Biochim et Biophys Acta (BBA) - Reviews Cancer"},{"issue":"12","key":"2707_CR63","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1089\/dna.2022.0486","volume":"41","author":"S Khoziainova","year":"2022","unstructured":"Khoziainova S, Rozenberg G, Levy M. Ketogenic Diet and Beta-Hydroxybutyrate in Colorectal Cancer. DNA Cell Biol. 2022;41(12):1007\u201311.","journal-title":"DNA Cell Biol"},{"issue":"1","key":"2707_CR64","doi-asserted-by":"publisher","first-page":"6201","DOI":"10.1038\/s41467-021-26431-4","volume":"12","author":"LCD Pomatto-Watson","year":"2021","unstructured":"Pomatto-Watson LCD, et al. Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary composition. Nat Commun. 2021;12(1):6201.","journal-title":"Nat Commun"},{"key":"2707_CR65","doi-asserted-by":"crossref","unstructured":"Dal Bello S et al. Ketogenic Diet in the Treatment of Gliomas and Glioblastomas. Nutrients, 2022. 14(18).","DOI":"10.3390\/nu14183851"},{"issue":"28","key":"2707_CR66","doi-asserted-by":"publisher","first-page":"43713","DOI":"10.18632\/oncotarget.9666","volume":"7","author":"S Shah","year":"2016","unstructured":"Shah S, et al. Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism. Oncotarget. 2016;7(28):43713\u201330.","journal-title":"Oncotarget"},{"issue":"2","key":"2707_CR67","doi-asserted-by":"publisher","first-page":"100069","DOI":"10.1016\/j.bneo.2025.100069","volume":"2","author":"V da Silva-Diz","year":"2025","unstructured":"da Silva-Diz V, et al. A feedforward loop between ACLY and MYC supports T-ALL progression in vivo. Blood Neoplasia. 2025;2(2):100069.","journal-title":"Blood Neoplasia"},{"key":"2707_CR68","doi-asserted-by":"crossref","unstructured":"Peyton KJ et al. The Glutamine-\u03b1-Ketoglutarate Metabolic Axis Controls Vascular Smooth Muscle Cell Function. Cells, 2026. 15(3).","DOI":"10.3390\/cells15030230"},{"issue":"12","key":"2707_CR69","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.4161\/epi.22713","volume":"7","author":"NE Simpson","year":"2012","unstructured":"Simpson NE, et al. Modifying metabolically sensitive histone marks by inhibiting glutamine metabolism affects gene expression and alters cancer cell phenotype. Epigenetics. 2012;7(12):1413\u201320.","journal-title":"Epigenetics"},{"issue":"7577","key":"2707_CR70","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature15520","volume":"527","author":"D Peng","year":"2015","unstructured":"Peng D, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015;527(7577):249\u201353.","journal-title":"Nature"},{"key":"2707_CR71","doi-asserted-by":"crossref","unstructured":"Lawand M et al. Messing with Signal 1: How Perturbed MHC Class I Antigen Presentation Contributes to Cancer. Cells, 2026. 15(7).","DOI":"10.3390\/cells15070653"},{"issue":"3","key":"2707_CR72","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ccell.2025.01.013","volume":"43","author":"P Porazzi","year":"2025","unstructured":"Porazzi P, et al. EZH1\/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer Cell. 2025;43(3):537\u201351. .e7.","journal-title":"Cancer Cell"},{"key":"2707_CR73","doi-asserted-by":"crossref","unstructured":"Lu C et al. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion. J Natl Cancer Inst, 2017. 109(6).","DOI":"10.1093\/jnci\/djw283"},{"key":"2707_CR74","doi-asserted-by":"crossref","unstructured":"Shi Q et al. Menin-MLL1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for Leukemia and Cancers. Molecules, 2023. 28(7).","DOI":"10.3390\/molecules28073026"},{"issue":"7987","key":"2707_CR75","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41586-023-06688-z","volume":"623","author":"S Zhao","year":"2023","unstructured":"Zhao S, et al. TNRC18 engages H3K9me3 to mediate silencing of endogenous retrotransposons. Nature. 2023;623(7987):633\u201342.","journal-title":"Nature"},{"issue":"15","key":"2707_CR76","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/0008-5472.CAN-21-3523","volume":"82","author":"D Pan","year":"2022","unstructured":"Pan D, et al. SETDB1 Restrains Endogenous Retrovirus Expression and Antitumor Immunity during Radiotherapy. Cancer Res. 2022;82(15):2748\u201360.","journal-title":"Cancer Res"},{"key":"2707_CR77","doi-asserted-by":"crossref","unstructured":"El Baba R, Herbein G. EZH2-Myc Hallmark in Oncovirus\/Cytomegalovirus Infections and Cytomegalovirus\u2019 Resemblance to Oncoviruses. Cells, 2024. 13(6).","DOI":"10.3390\/cells13060541"},{"issue":"2Supplement","key":"2707_CR78","doi-asserted-by":"publisher","first-page":"A087","DOI":"10.1158\/1538-7445.PANCA2023-A087","volume":"84","author":"J Chen","year":"2024","unstructured":"Chen J, et al. Abstract A087: Loss of KDM5A supports KRAS-driven pancreatic cancer. Cancer Res. 2024;84(2Supplement):A087\u2013087.","journal-title":"Cancer Res"},{"issue":"12","key":"2707_CR79","doi-asserted-by":"publisher","first-page":"104220","DOI":"10.1016\/j.drudis.2024.104220","volume":"29","author":"R Wu","year":"2024","unstructured":"Wu R, et al. Metabolic reprogramming in KRAS-mutant cancers: Proven targetable vulnerabilities and potential therapeutic strategies. Drug Discovery Today. 2024;29(12):104220.","journal-title":"Drug Discovery Today"},{"issue":"12","key":"2707_CR80","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1158\/2159-8290.CD-23-0866","volume":"14","author":"P Loi","year":"2024","unstructured":"Loi P, et al. Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers. Cancer Discov. 2024;14(12):2430\u201349.","journal-title":"Cancer Discov"},{"issue":"5","key":"2707_CR81","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41419-023-05832-x","volume":"14","author":"Y Fukui","year":"2023","unstructured":"Fukui Y, et al. The EZH2\u2013PRC2\u2013H3K27me3 axis governs the endometrial cell cycle and differentiation for blastocyst invasion. Cell Death Dis. 2023;14(5):320.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2707_CR82","doi-asserted-by":"publisher","first-page":"9565","DOI":"10.1038\/s41467-025-65439-y","volume":"16","author":"JL Walshe","year":"2025","unstructured":"Walshe JL, et al. Molecular mechanism of co-transcriptional H3K36 methylation by SETD2. Nat Commun. 2025;16(1):9565.","journal-title":"Nat Commun"},{"key":"2707_CR83","doi-asserted-by":"crossref","unstructured":"Verza FA et al. Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy. Cancers (Basel), 2020. 12(6).","DOI":"10.3390\/cancers12061664"},{"issue":"1","key":"2707_CR84","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13072-025-00624-3","volume":"18","author":"X Chen","year":"2025","unstructured":"Chen X, et al. Roles of KDM5 demethylases in therapeutic resistance of cancers. Epigenetics Chromatin. 2025;18(1):61.","journal-title":"Epigenetics Chromatin"},{"issue":"4","key":"2707_CR85","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jcmgh.2022.12.001","volume":"15","author":"HM Kolev","year":"2023","unstructured":"Kolev HM, et al. H3K27me3 Demethylases Maintain the Transcriptional and Epigenomic Landscape of the Intestinal Epithelium. Cell Mol Gastroenterol Hepatol. 2023;15(4):821\u201339.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"15","key":"2707_CR86","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1016\/j.molcel.2025.06.025","volume":"85","author":"C-C Lin","year":"2025","unstructured":"Lin C-C, et al. Structural mechanism of H3K27 demethylation and crosstalk with heterochromatin markers. Mol Cell. 2025;85(15):2869\u201384. .e6.","journal-title":"Mol Cell"},{"issue":"20","key":"2707_CR87","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1111\/febs.16580","volume":"290","author":"A Kotekar","year":"2023","unstructured":"Kotekar A, Singh AK, Devaiah BN. BRD4 and MYC: power couple in transcription and disease. FEBS J. 2023;290(20):4820\u201342.","journal-title":"FEBS J"},{"key":"2707_CR88","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ebiom.2016.04.017","volume":"8","author":"R Zhao","year":"2016","unstructured":"Zhao R, et al. Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer. EBioMedicine. 2016;8:30\u20139.","journal-title":"EBioMedicine"},{"key":"2707_CR89","doi-asserted-by":"publisher","first-page":"w20329","DOI":"10.4414\/smw.2020.20329","volume":"150","author":"ID Karemaker","year":"2020","unstructured":"Karemaker ID, Baubec T. DNA methyltransferases hitchhiking on chromatin. Swiss Med Wkly. 2020;150:w20329.","journal-title":"Swiss Med Wkly"},{"issue":"12","key":"2707_CR90","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1038\/sj.bjc.6604374","volume":"98","author":"L Lopez-Serra","year":"2008","unstructured":"Lopez-Serra L, Esteller M. Proteins that bind methylated DNA and human cancer: reading the wrong words. Br J Cancer. 2008;98(12):1881\u20135.","journal-title":"Br J Cancer"},{"issue":"6","key":"2707_CR91","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2217\/epi.15.39","volume":"7","author":"Q Du","year":"2015","unstructured":"Du Q, et al. Methyl-CpG-binding domain proteins: readers of the epigenome. Epigenomics. 2015;7(6):1051\u201373.","journal-title":"Epigenomics"},{"issue":"1","key":"2707_CR92","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41392-025-02266-z","volume":"10","author":"J Song","year":"2025","unstructured":"Song J, et al. Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance. Signal Transduct Target Ther. 2025;10(1):219.","journal-title":"Signal Transduct Target Ther"},{"issue":"16","key":"2707_CR93","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1038\/onc.2010.568","volume":"30","author":"Y Kotake","year":"2011","unstructured":"Kotake Y, et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene. 2011;30(16):1956\u201362.","journal-title":"Oncogene"},{"issue":"1","key":"2707_CR94","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10555-025-10253-7","volume":"44","author":"A Suraweera","year":"2025","unstructured":"Suraweera A, O\u2019Byrne KJ, Richard DJ. Epigenetic drugs in cancer therapy. Cancer Metastasis Rev. 2025;44(1):37.","journal-title":"Cancer Metastasis Rev"},{"issue":"9","key":"2707_CR95","doi-asserted-by":"publisher","first-page":"671","DOI":"10.2217\/epi-2023-0443","volume":"16","author":"N Zohourian","year":"2024","unstructured":"Zohourian N, Brown JA. Current trends in clinical trials and the development of small molecule epigenetic inhibitors as cancer therapeutics. Epigenomics. 2024;16(9):671\u201380.","journal-title":"Epigenomics"},{"issue":"1","key":"2707_CR96","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","volume":"10","author":"X Yu","year":"2024","unstructured":"Yu X, et al. Cancer epigenetics: from laboratory studies and clinical trials to precision medicine. Cell Death Discov. 2024;10(1):28.","journal-title":"Cell Death Discov"},{"key":"2707_CR97","doi-asserted-by":"crossref","unstructured":"Rossi A et al. Progresses and Pitfalls of Epigenetics in Solid Tumors Clinical Trials. Int J Mol Sci, 2024. 25(21).","DOI":"10.3390\/ijms252111740"},{"issue":"Supplement 1","key":"2707_CR98","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1182\/blood-2024-208735","volume":"144","author":"S Waris","year":"2024","unstructured":"Waris S, et al. Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndrome: A Propensity Score-Matched Retrospective Cohort Study Using Trinetx. Blood. 2024;144(Supplement 1):4603\u20134603.","journal-title":"Blood"},{"key":"2707_CR99","doi-asserted-by":"publisher","first-page":"107057","DOI":"10.1016\/j.ejps.2025.107057","volume":"208","author":"N El Omari","year":"2025","unstructured":"El Omari N, et al. Clinical efficacy and mechanistic insights of FDA-approved HDAC inhibitors in the treatment of lymphoma. Eur J Pharm Sci. 2025;208:107057.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"2707_CR100","doi-asserted-by":"publisher","first-page":"35880","DOI":"10.1038\/s41598-025-19717-w","volume":"15","author":"R Begum","year":"2025","unstructured":"Begum R, Parsons JL, Jones AM. Adverse drug reaction profiles of histone deacetylase inhibitors. Sci Rep. 2025;15(1):35880.","journal-title":"Sci Rep"},{"issue":"Supplement 1","key":"2707_CR101","doi-asserted-by":"publisher","first-page":"7109","DOI":"10.1182\/blood-2025-7109","volume":"146","author":"N Pokharel","year":"2025","unstructured":"Pokharel N, et al. Tazemetostat in Relapsed\/Refractory follicular lymphoma and DLBCL: A systematic review of clinical trials. Blood. 2025;146(Supplement 1):7109\u20137109.","journal-title":"Blood"},{"issue":"5","key":"2707_CR102","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s41591-025-03572-3","volume":"31","author":"RK Rampal","year":"2025","unstructured":"Rampal RK, et al. Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial. Nat Med. 2025;31(5):1531\u20138.","journal-title":"Nat Med"},{"key":"2707_CR103","doi-asserted-by":"crossref","unstructured":"Wang X et al. Pharmacological inhibition of the acetyltransferase Tip60 mitigates myocardial infarction injury. Dis Model Mech, 2023. 16(5).","DOI":"10.1242\/dmm.049786"},{"issue":"7327","key":"2707_CR104","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067\u201373.","journal-title":"Nature"},{"issue":"16","key":"2707_CR105","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.4161\/cc.6.16.4554","volume":"6","author":"B Gargano","year":"2007","unstructured":"Gargano B, et al. P-TEFb is a crucial co-factor for Myc transactivation. Cell Cycle. 2007;6(16):2031\u20137.","journal-title":"Cell Cycle"},{"issue":"8","key":"2707_CR106","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1158\/0008-5472.CAN-23-1836","volume":"84","author":"Y Chen","year":"2024","unstructured":"Chen Y, et al. Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer-Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression. Cancer Res. 2024;84(8):1237\u201351.","journal-title":"Cancer Res"},{"issue":"8","key":"2707_CR107","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","volume":"28","author":"DB Doroshow","year":"2017","unstructured":"Doroshow DB, Eder JP, LoRusso PM. BET inhibitors: a novel epigenetic approach. Ann Oncol. 2017;28(8):1776\u201387.","journal-title":"Ann Oncol"},{"issue":"5","key":"2707_CR108","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.celrep.2016.06.091","volume":"16","author":"AM Kurimchak","year":"2016","unstructured":"Kurimchak AM, et al. Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. Cell Rep. 2016;16(5):1273\u201386.","journal-title":"Cell Rep"},{"key":"2707_CR109","doi-asserted-by":"crossref","unstructured":"Bowry A et al. BET Inhibition Induces HEXIM1- and RAD51-Dependent Conflicts between Transcription and Replication. Cell Rep, 2018. 25(8): p. 2061\u20132069.e4.","DOI":"10.1016\/j.celrep.2018.10.079"},{"issue":"1","key":"2707_CR110","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","volume":"33","author":"M Kleppe","year":"2018","unstructured":"Kleppe M, et al. Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell. 2018;33(1):29\u2013e437.","journal-title":"Cancer Cell"},{"issue":"5","key":"2707_CR111","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/ajh.26889","volume":"98","author":"D Ivanov","year":"2023","unstructured":"Ivanov D, et al. Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms. Am J Hematol. 2023;98(5):770\u201383.","journal-title":"Am J Hematol"},{"key":"2707_CR112","doi-asserted-by":"publisher","first-page":"112904","DOI":"10.1016\/j.ejmech.2020.112904","volume":"209","author":"AKA Bass","year":"2021","unstructured":"Bass AKA, et al. Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. Eur J Med Chem. 2021;209:112904.","journal-title":"Eur J Med Chem"},{"key":"2707_CR113","doi-asserted-by":"publisher","first-page":"100221","DOI":"10.1016\/j.medidd.2025.100221","volume":"27","author":"V Mathur","year":"2025","unstructured":"Mathur V, et al. Design and development of PROTACs: A new paradigm in anticancer drug discovery. Med Drug Discovery. 2025;27:100221.","journal-title":"Med Drug Discovery"},{"key":"2707_CR114","doi-asserted-by":"crossref","unstructured":"Luo H et al. Advancing Design Strategy of PROTACs for Cancer Therapy. MedComm (2020), 2025. 6(7): p. e70258.","DOI":"10.1002\/mco2.70258"},{"issue":"21","key":"2707_CR115","doi-asserted-by":"publisher","first-page":"e70132","DOI":"10.1002\/cncr.70132","volume":"131","author":"YA Anaya","year":"2025","unstructured":"Anaya YA, et al. Proteolysis-targeting chimeras in cancer therapy: Targeted protein degradation for next-generation treatment. Cancer. 2025;131(21):e70132.","journal-title":"Cancer"},{"key":"2707_CR116","doi-asserted-by":"publisher","first-page":"116154","DOI":"10.1016\/j.ejmech.2024.116154","volume":"267","author":"J Velez","year":"2024","unstructured":"Velez J, et al. Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2. Eur J Med Chem. 2024;267:116154.","journal-title":"Eur J Med Chem"},{"issue":"4","key":"2707_CR117","first-page":"409","volume":"2","author":"C Zhang","year":"2023","unstructured":"Zhang C, et al. PROTACs Targeting Epigenetic Proteins. Acta Mater Med. 2023;2(4):409\u201329.","journal-title":"Acta Mater Med"},{"issue":"1","key":"2707_CR118","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s42004-025-01598-9","volume":"8","author":"ATS Vicente","year":"2025","unstructured":"Vicente ATS, Moura S, Salvador JAR. Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs. Commun Chem. 2025;8(1):218.","journal-title":"Commun Chem"},{"issue":"3","key":"2707_CR119","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41589-022-01177-2","volume":"19","author":"A Hanzl","year":"2023","unstructured":"Hanzl A, et al. Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders. Nat Chem Biol. 2023;19(3):323\u201333.","journal-title":"Nat Chem Biol"},{"key":"2707_CR120","doi-asserted-by":"publisher","first-page":"115830","DOI":"10.1016\/j.ejmech.2023.115830","volume":"261","author":"H Zhao","year":"2023","unstructured":"Zhao H. Kinetic modelling of the P-glycoprotein mediated efflux with a large-scale matched molecular pair analysis. Eur J Med Chem. 2023;261:115830.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"2707_CR121","doi-asserted-by":"publisher","first-page":"6509","DOI":"10.1038\/s41467-023-42233-2","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. Expanding PROTACtable genome universe of E3 ligases. Nat Commun. 2023;14(1):6509.","journal-title":"Nat Commun"},{"issue":"11","key":"2707_CR122","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s41589-021-00878-4","volume":"17","author":"S Imaide","year":"2021","unstructured":"Imaide S, et al. Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity. Nat Chem Biol. 2021;17(11):1157\u201367.","journal-title":"Nat Chem Biol"},{"issue":"22","key":"2707_CR123","doi-asserted-by":"publisher","first-page":"9243","DOI":"10.1039\/D2CS00362G","volume":"51","author":"D Lu","year":"2022","unstructured":"Lu D, et al. Applications of covalent chemistry in targeted protein degradation. Chem Soc Rev. 2022;51(22):9243\u201361.","journal-title":"Chem Soc Rev"},{"issue":"19","key":"2707_CR124","doi-asserted-by":"publisher","first-page":"7380","DOI":"10.1021\/jacs.1c00451","volume":"143","author":"J Liu","year":"2021","unstructured":"Liu J, et al. Cancer Selective Target Degradation by Folate-Caged PROTACs. J Am Chem Soc. 2021;143(19):7380\u20137.","journal-title":"J Am Chem Soc"},{"issue":"6","key":"2707_CR125","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.chembiol.2024.04.002","volume":"31","author":"M Konstantinidou","year":"2024","unstructured":"Konstantinidou M, Arkin MR. Molecular glues for protein-protein interactions: Progressing toward a new dream. Cell Chem Biol. 2024;31(6):1064\u201388.","journal-title":"Cell Chem Biol"},{"key":"2707_CR126","doi-asserted-by":"publisher","first-page":"118219","DOI":"10.1016\/j.bmc.2025.118219","volume":"127","author":"B Lv","year":"2025","unstructured":"Lv B, et al. Dual inhibitors of butyrylcholinesterase and histone deacetylase 6 for the treatment of Alzheimer\u2019s disease: design, synthesis, and biological evaluation. Bioorg Med Chem. 2025;127:118219.","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"2707_CR127","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/17568919.2024.2437975","volume":"17","author":"WB Liu","year":"2025","unstructured":"Liu WB, Song J, Zhang SY. A short overview of dual targeting HDAC inhibitors. Future Med Chem. 2025;17(1):5\u20137.","journal-title":"Future Med Chem"},{"key":"2707_CR128","doi-asserted-by":"publisher","first-page":"102758","DOI":"10.1016\/j.sbi.2023.102758","volume":"84","author":"W-V Tee","year":"2024","unstructured":"Tee W-V, Berezovsky IN. Allosteric drugs: New principles and design approaches. Curr Opin Struct Biol. 2024;84:102758.","journal-title":"Curr Opin Struct Biol"},{"issue":"20","key":"2707_CR129","doi-asserted-by":"publisher","first-page":"169180","DOI":"10.1016\/j.jmb.2025.169180","volume":"437","author":"S Li","year":"2025","unstructured":"Li S, et al. Deciphering Allosteric Modulation of Cancer-Associated Histone Missense Mutations. J Mol Biol. 2025;437(20):169180.","journal-title":"J Mol Biol"},{"issue":"5","key":"2707_CR130","doi-asserted-by":"publisher","first-page":"101020","DOI":"10.1016\/j.gendis.2023.04.040","volume":"11","author":"D Wang","year":"2024","unstructured":"Wang D, et al. Epigenetics: Mechanisms, potential roles, and therapeutic strategies in cancer progression. Genes Dis. 2024;11(5):101020.","journal-title":"Genes Dis"},{"issue":"23","key":"2707_CR131","doi-asserted-by":"publisher","first-page":"5638","DOI":"10.7150\/jca.34471","volume":"10","author":"T Sun","year":"2019","unstructured":"Sun T, et al. Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells. J Cancer. 2019;10(23):5638\u201345.","journal-title":"J Cancer"},{"issue":"22","key":"2707_CR132","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2217\/epi-2022-0320","volume":"14","author":"R Huang","year":"2022","unstructured":"Huang R, Wu Y, Zou Z. Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects. Epigenomics. 2022;14(22):1449\u201364.","journal-title":"Epigenomics"},{"issue":"10","key":"2707_CR133","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1158\/1535-7163.MCT-24-0693","volume":"24","author":"M Melino","year":"2025","unstructured":"Melino M, et al. Depleting the Action of EZH2 through PI3K-mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer. Mol Cancer Ther. 2025;24(10):1511\u201326.","journal-title":"Mol Cancer Ther"},{"key":"2707_CR134","doi-asserted-by":"publisher","first-page":"965244","DOI":"10.3389\/fphar.2022.965244","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, et al. Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges. Front Pharmacol. 2022;13:965244.","journal-title":"Front Pharmacol"},{"issue":"16suppl","key":"2707_CR135","doi-asserted-by":"publisher","first-page":"10003","DOI":"10.1200\/JCO.2025.43.16_suppl.10003","volume":"43","author":"A Arakawa","year":"2025","unstructured":"Arakawa A, et al. Safety and efficacy of the EZH1\/2 inhibitor valemetostat tosylate (DS-3201b) in pediatric patients with malignant solid tumors (NCCH1904): A multicenter phase I trial. J Clin Oncol. 2025;43(16suppl):10003\u201310003.","journal-title":"J Clin Oncol"},{"key":"2707_CR136","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1182\/blood-2025-780","volume":"146","author":"T Xu","year":"2025","unstructured":"Xu T, et al. A prospective clinical study on the combination of anti-PD1 monoclonal antibody with lenalidomide and azacitidine for the treatment of relapsed\/refractory peripheral T-cell lymphoma. Blood. 2025;146:780.","journal-title":"Blood"},{"issue":"7","key":"2707_CR137","first-page":"1628","volume":"110","author":"IM Bouligny","year":"2025","unstructured":"Bouligny IM, et al. A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome. Haematologica. 2025;110(7):1628\u201333.","journal-title":"Haematologica"},{"issue":"1","key":"2707_CR138","doi-asserted-by":"publisher","first-page":"9801","DOI":"10.1038\/s41467-024-52528-7","volume":"15","author":"M Baretti","year":"2024","unstructured":"Baretti M, et al. Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial. Nat Commun. 2024;15(1):9801.","journal-title":"Nat Commun"},{"issue":"2","key":"2707_CR139","doi-asserted-by":"publisher","first-page":"158","DOI":"10.6004\/jadpro.2022.13.2.7","volume":"13","author":"R Straining","year":"2022","unstructured":"Straining R, Eighmy W. Tazemetostat: EZH2 Inhibitor. J Adv Pract Oncol. 2022;13(2):158\u201363.","journal-title":"J Adv Pract Oncol"},{"key":"2707_CR140","doi-asserted-by":"crossref","unstructured":"Oppelt PJ et al. Tazemetostat, a Selective EZH2 Inhibitor, in Combination with Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 1 Trial. Cancers (Basel), 2025. 17(3).","DOI":"10.3390\/cancers17030437"},{"issue":"3","key":"2707_CR141","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41375-023-01808-0","volume":"37","author":"KA Romine","year":"2023","unstructured":"Romine KA, et al. BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8(+) T cells. Leukemia. 2023;37(3):580\u201392.","journal-title":"Leukemia"},{"issue":"1","key":"2707_CR142","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1186\/s12885-025-13851-4","volume":"25","author":"D Marbach","year":"2025","unstructured":"Marbach D, et al. Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor). BMC Cancer. 2025;25(1):500.","journal-title":"BMC Cancer"},{"issue":"20","key":"2707_CR143","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1158\/1078-0432.CCR-22-1128","volume":"28","author":"JB Hiatt","year":"2022","unstructured":"Hiatt JB, et al. Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing. Clin Cancer Res. 2022;28(20):4551\u201364.","journal-title":"Clin Cancer Res"},{"issue":"48","key":"2707_CR144","doi-asserted-by":"publisher","first-page":"79217","DOI":"10.18632\/oncotarget.12640","volume":"7","author":"PY Liu","year":"2016","unstructured":"Liu PY, et al. The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs. Oncotarget. 2016;7(48):79217\u201332.","journal-title":"Oncotarget"},{"issue":"3","key":"2707_CR145","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41389-020-0218-z","volume":"9","author":"S Zhou","year":"2020","unstructured":"Zhou S, et al. BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2\/NID1 signaling. Oncogenesis. 2020;9(3):33.","journal-title":"Oncogenesis"},{"issue":"1","key":"2707_CR146","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s43556-025-00373-5","volume":"6","author":"C Ma","year":"2025","unstructured":"Ma C, et al. Epigenetic drugs in cancer therapy: mechanisms, immune modulation, and therapeutic applications. Mol Biomed. 2025;6(1):132.","journal-title":"Mol Biomed"},{"issue":"8002","key":"2707_CR147","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-024-07103-x","volume":"627","author":"M Yamagishi","year":"2024","unstructured":"Yamagishi M, et al. Mechanisms of action and resistance in histone methylation-targeted therapy. Nature. 2024;627(8002):221\u20138.","journal-title":"Nature"},{"issue":"12","key":"2707_CR148","doi-asserted-by":"publisher","first-page":"111359","DOI":"10.1016\/j.isci.2024.111359","volume":"27","author":"Y Gao","year":"2024","unstructured":"Gao Y, et al. Crosstalk between metabolic and epigenetic modifications during cell carcinogenesis. iScience. 2024;27(12):111359.","journal-title":"iScience"},{"issue":"1","key":"2707_CR149","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41392-025-02266-z","volume":"10","author":"J Song","year":"2025","unstructured":"Song J, et al. Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance. Signal Transduct Target Therapy. 2025;10(1):219.","journal-title":"Signal Transduct Target Therapy"},{"key":"2707_CR150","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.canlet.2017.10.015","volume":"413","author":"S Wen","year":"2018","unstructured":"Wen S, et al. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo. Cancer Lett. 2018;413:35\u201345.","journal-title":"Cancer Lett"},{"key":"2707_CR151","doi-asserted-by":"crossref","unstructured":"Guo Z et al. Differential regulation of FADS2 by EZH2 reveals a metabolic vulnerability in ovarian cancer treatment. eBioMedicine, 2025. 119.","DOI":"10.1016\/j.ebiom.2025.105879"},{"key":"2707_CR152","unstructured":"Parkhitko AA et al. Methionine restriction and mimetics to ameliorate human aging and disease. Trends in Endocrinology & Metabolism."},{"issue":"4","key":"2707_CR153","doi-asserted-by":"publisher","first-page":"104229","DOI":"10.1016\/j.xpro.2025.104229","volume":"6","author":"HJ Shin","year":"2025","unstructured":"Shin HJ, et al. Protocol to track single-cell-derived clones using DNA barcoding combined with single-cell RNA sequencing. STAR Protocols. 2025;6(4):104229.","journal-title":"STAR Protocols"},{"issue":"8","key":"2707_CR154","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.tibtech.2024.02.007","volume":"42","author":"T Clark","year":"2024","unstructured":"Clark T, et al. CRISPR activation screens: navigating technologies and applications. Trends Biotechnol. 2024;42(8):1017\u201334.","journal-title":"Trends Biotechnol"},{"issue":"1","key":"2707_CR155","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1038\/s42003-024-07277-0","volume":"7","author":"A Reyes-Oliveras","year":"2024","unstructured":"Reyes-Oliveras A, et al. Metabolomics and 13\u00a0C labelled glucose tracing to identify carbon incorporation into aberrant cell membrane glycans in cancer. Commun Biology. 2024;7(1):1576.","journal-title":"Commun Biology"},{"issue":"23","key":"2707_CR156","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1158\/0008-5472.CAN-23-1475","volume":"83","author":"Y Huang","year":"2023","unstructured":"Huang Y, et al. EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes. Cancer Res. 2023;83(23):3956\u201373.","journal-title":"Cancer Res"},{"issue":"5","key":"2707_CR157","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1158\/1535-7163.MCT-21-0646","volume":"21","author":"Y Ishi","year":"2022","unstructured":"Ishi Y, et al. Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors. Mol Cancer Ther. 2022;21(5):715\u201326.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2707_CR158","doi-asserted-by":"publisher","first-page":"2163242","DOI":"10.1080\/14756366.2022.2163242","volume":"38","author":"A Negri","year":"2023","unstructured":"Negri A, et al. Simultaneous administration of EZH2 and BET inhibitors inhibits proliferation and clonogenic ability of metastatic prostate cancer cells. J Enzyme Inhib Med Chem. 2023;38(1):2163242.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"2707_CR159","unstructured":"Calcagno E et al. Unlocking the synergistic potential of HAT activation and HDAC inhibition for rescuing memory deficits in Alzheimer\u2019s Disease. LID - e087929. (1552\u20135260 (Print))."},{"issue":"1","key":"2707_CR160","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13148-021-01098-2","volume":"13","author":"T Yang","year":"2021","unstructured":"Yang T, Yang Y, Wang Y. Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy. Clin Epigenetics. 2021;13(1):113.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"2707_CR161","doi-asserted-by":"publisher","first-page":"8733","DOI":"10.1038\/s41467-025-64445-4","volume":"16","author":"CD Rouault","year":"2025","unstructured":"Rouault CD, Charafe-Jauffret E, Ginestier C. The interplay of DNA damage, epigenetics and tumour heterogeneity in driving cancer cell fitness. Nat Commun. 2025;16(1):8733.","journal-title":"Nat Commun"},{"key":"2707_CR162","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40364-019-0174-y","volume":"7","author":"M Guo","year":"2019","unstructured":"Guo M, et al. Epigenetic heterogeneity in cancer. Biomark Res. 2019;7:23.","journal-title":"Biomark Res"},{"issue":"1","key":"2707_CR163","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-025-01453-5","volume":"17","author":"Q Luo","year":"2025","unstructured":"Luo Q, Teschendorff AE. Cell-type-specific subtyping of epigenomes improves prognostic stratification of cancer. Genome Med. 2025;17(1):34.","journal-title":"Genome Med"},{"issue":"14","key":"2707_CR164","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1182\/bloodadvances.2021006069","volume":"6","author":"CM Bourne","year":"2022","unstructured":"Bourne CM, et al. Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment. Blood Adv. 2022;6(14):4107\u201321.","journal-title":"Blood Adv"},{"key":"2707_CR165","doi-asserted-by":"publisher","first-page":"103399","DOI":"10.1016\/j.eclinm.2025.103399","volume":"87","author":"J Cao","year":"2025","unstructured":"Cao J, et al. Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed\/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study. EClinicalMedicine. 2025;87:103399.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"2707_CR166","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41392-025-02299-4","volume":"10","author":"S Singh","year":"2025","unstructured":"Singh S, et al. Glioblastoma at the crossroads: current understanding and future therapeutic horizons. Signal Transduct Target Ther. 2025;10(1):213.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"2707_CR167","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10555-025-10288-w","volume":"44","author":"A Chaudhary","year":"2025","unstructured":"Chaudhary A, et al. Precision epigenetic therapies in oncology. Cancer Metastasis Rev. 2025;44(4):71.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"2707_CR168","doi-asserted-by":"publisher","first-page":"11727","DOI":"10.1038\/s41598-022-15417-x","volume":"12","author":"K Susami","year":"2022","unstructured":"Susami K, et al. Genome-wide profiling of histone H3K4me3 and H3K27me3 modifications in individual blastocysts by CUT&Tag without a solid support (NON-TiE-UP CUT&Tag). Sci Rep. 2022;12(1):11727.","journal-title":"Sci Rep"},{"issue":"1","key":"2707_CR169","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13072-025-00616-3","volume":"18","author":"AR de Abreu","year":"2025","unstructured":"de Abreu AR, et al. Comparison of current methods for genome-wide DNA methylation profiling. Epigenetics Chromatin. 2025;18(1):57.","journal-title":"Epigenetics Chromatin"},{"issue":"6","key":"2707_CR170","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1038\/s41596-022-00692-9","volume":"17","author":"FC Grandi","year":"2022","unstructured":"Grandi FC, et al. Chromatin accessibility profiling by ATAC-seq. Nat Protoc. 2022;17(6):1518\u201352.","journal-title":"Nat Protoc"},{"issue":"1","key":"2707_CR171","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s40364-024-00643-4","volume":"12","author":"X Wu","year":"2024","unstructured":"Wu X, et al. Single-cell sequencing to multi-omics: technologies and applications. Biomark Res. 2024;12(1):110.","journal-title":"Biomark Res"},{"issue":"6","key":"2707_CR172","doi-asserted-by":"publisher","first-page":"MSB178124","DOI":"10.15252\/msb.20178124","volume":"14","author":"R Argelaguet","year":"2018","unstructured":"Argelaguet R, et al. Multi-Omics Factor Analysis\u2014a framework for unsupervised integration of multi\u2010omics data sets. Mol Syst Biol. 2018;14(6):MSB178124.","journal-title":"Mol Syst Biol"},{"issue":"1","key":"2707_CR173","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/biostatistics\/kxx017","volume":"19","author":"Q Mo","year":"2018","unstructured":"Mo Q, et al. A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. Biostatistics. 2018;19(1):71\u201386.","journal-title":"Biostatistics"},{"issue":"3","key":"2707_CR174","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nmeth.2810","volume":"11","author":"B Wang","year":"2014","unstructured":"Wang B, et al. Similarity network fusion for aggregating data types on a genomic scale. Nat Methods. 2014;11(3):333\u20137.","journal-title":"Nat Methods"},{"issue":"1","key":"2707_CR175","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s41060-025-00957-y","volume":"21","author":"J Gillariose","year":"2025","unstructured":"Gillariose J, Joseph J, Chesneau C. Lasso and Ridge regression: a comprehensive review of applications and developments in machine learning. Int J Data Sci Analytics. 2025;21(1):7.","journal-title":"Int J Data Sci Analytics"},{"key":"2707_CR176","doi-asserted-by":"publisher","first-page":"1510829","DOI":"10.3389\/fimmu.2024.1510829","volume":"15","author":"X Guo","year":"2024","unstructured":"Guo X, et al. Epigenetic profiling for prognostic stratification and personalized therapy in breast cancer. Front Immunol. 2024;15:1510829.","journal-title":"Front Immunol"},{"issue":"1","key":"2707_CR177","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1038\/s41467-024-47701-x","volume":"15","author":"P Romero","year":"2024","unstructured":"Romero P, et al. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition. Nat Commun. 2024;15(1):3452.","journal-title":"Nat Commun"},{"issue":"15","key":"2707_CR178","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1158\/0008-5472.CAN-18-0814","volume":"78","author":"B Tang","year":"2018","unstructured":"Tang B, et al. Specific Targeting of MTAP-Deleted Tumors with a Combination of 2\u2019-Fluoroadenine and 5\u2019-Methylthioadenosine. Cancer Res. 2018;78(15):4386\u201395.","journal-title":"Cancer Res"},{"issue":"3","key":"2707_CR179","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/carcin\/bgad011","volume":"44","author":"X Zhang","year":"2023","unstructured":"Zhang X, et al. ARID1A mutations in cancer development: mechanism and therapy. Carcinogenesis. 2023;44(3):197\u2013208.","journal-title":"Carcinogenesis"},{"key":"2707_CR180","doi-asserted-by":"crossref","unstructured":"Weng YY, Huang MY. The CpG Island Methylator Phenotype Status in Synchronous and Solitary Primary Colorectal Cancers: Prognosis and Effective Therapeutic Drug Prediction. Int J Mol Sci, 2024. 25(10).","DOI":"10.3390\/ijms25105243"},{"issue":"4","key":"2707_CR181","doi-asserted-by":"publisher","first-page":"100180","DOI":"10.1016\/j.cellin.2024.100180","volume":"3","author":"L Jiang","year":"2024","unstructured":"Jiang L, Huang L, Jiang W. H3K27me3-mediated epigenetic regulation in pluripotency maintenance and lineage differentiation. Cell Insight. 2024;3(4):100180.","journal-title":"Cell Insight"},{"issue":"22","key":"2707_CR182","doi-asserted-by":"publisher","first-page":"e2201883119","DOI":"10.1073\/pnas.2201883119","volume":"119","author":"K Kraft","year":"2022","unstructured":"Kraft K, et al. Polycomb-mediated genome architecture enables long-range spreading of H3K27 methylation. Proc Natl Acad Sci U S A. 2022;119(22):e2201883119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2707_CR183","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13072-025-00570-0","volume":"18","author":"Y Liang","year":"2025","unstructured":"Liang Y, et al. Comprehensive analysis of H3K27me3 LOCKs under different DNA methylation contexts reveal epigenetic redistribution in tumorigenesis. Epigenetics Chromatin. 2025;18(1):6.","journal-title":"Epigenetics Chromatin"},{"key":"2707_CR184","unstructured":"Wang Z, Zheng C et al. 2025, Springer US: New York, NY. 241\u20139."},{"issue":"3","key":"2707_CR185","doi-asserted-by":"publisher","first-page":"101529","DOI":"10.1016\/j.xpro.2022.101529","volume":"3","author":"A Panday","year":"2022","unstructured":"Panday A, et al. A modified CUT&RUN-seq technique for qPCR analysis of chromatin-protein interactions. STAR Protoc. 2022;3(3):101529.","journal-title":"STAR Protoc"},{"issue":"1","key":"2707_CR186","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1038\/s41467-023-40873-y","volume":"14","author":"KK Bendixen","year":"2023","unstructured":"Bendixen KK, et al. A qPCR technology for direct quantification of methylation in untreated DNA. Nat Commun. 2023;14(1):5153.","journal-title":"Nat Commun"},{"issue":"5","key":"2707_CR187","doi-asserted-by":"publisher","first-page":"152389","DOI":"10.1016\/j.seminoncol.2025.152389","volume":"52","author":"A Sharma","year":"2025","unstructured":"Sharma A, et al. From tissue architecture to clinical insights: Spatial transcriptomics in solid tumor studies. Semin Oncol. 2025;52(5):152389.","journal-title":"Semin Oncol"},{"key":"2707_CR188","doi-asserted-by":"crossref","unstructured":"Foo J et al. Roadmap on plasticity and epigenetics in cancer. Phys Biol, 2022. 19(3).","DOI":"10.1088\/1478-3975\/ac4ee2"},{"issue":"6","key":"2707_CR189","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/bioinformatics\/btz833","volume":"36","author":"SC Zheng","year":"2019","unstructured":"Zheng SC, et al. EpiDISH web server: Epigenetic Dissection of Intra-Sample-Heterogeneity with online GUI. Bioinformatics. 2019;36(6):1950\u20131.","journal-title":"Bioinformatics"},{"issue":"3","key":"2707_CR190","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1158\/1535-7163.MCT-17-0437","volume":"17","author":"BA Jones","year":"2018","unstructured":"Jones BA, Varambally S, Arend RC. Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer. Mol Cancer Ther. 2018;17(3):591\u2013602.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2707_CR191","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","volume":"31","author":"EE Gardner","year":"2017","unstructured":"Gardner EE, et al. Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. Cancer Cell. 2017;31(2):286\u201399.","journal-title":"Cancer Cell"},{"issue":"1","key":"2707_CR192","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12935-023-03154-8","volume":"23","author":"S Lu","year":"2023","unstructured":"Lu S, et al. The effects of ARID1A mutation in gastric cancer and its significance for treatment. Cancer Cell Int. 2023;23(1):296.","journal-title":"Cancer Cell Int"},{"issue":"19","key":"2707_CR193","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/pmic.201400060","volume":"14","author":"Y Zheng","year":"2014","unstructured":"Zheng Y, et al. Site-specific human histone H3 methylation stability: fast K4me3 turnover. Proteomics. 2014;14(19):2190\u20139.","journal-title":"Proteomics"},{"key":"2707_CR194","doi-asserted-by":"publisher","first-page":"992","DOI":"10.3389\/fphar.2020.00992","volume":"11","author":"SH Akone","year":"2020","unstructured":"Akone SH, et al. Natural Products Impacting DNA Methyltransferases and Histone Deacetylases. Front Pharmacol. 2020;11:992.","journal-title":"Front Pharmacol"},{"key":"2707_CR195","doi-asserted-by":"crossref","unstructured":"Arif KMT et al. Regulatory Mechanisms of Epigenetic miRNA Relationships in Human Cancer and Potential as Therapeutic Targets. Cancers (Basel), 2020. 12(10).","DOI":"10.3390\/cancers12102922"},{"issue":"1","key":"2707_CR196","doi-asserted-by":"publisher","first-page":"2491316","DOI":"10.1080\/15592294.2025.2491316","volume":"20","author":"S Roy","year":"2025","unstructured":"Roy S, et al. An overview of potential of natural compounds to regulate epigenetic modifications in colorectal cancer: a recent update. Epigenetics. 2025;20(1):2491316.","journal-title":"Epigenetics"},{"issue":"1","key":"2707_CR197","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13020-025-01124-y","volume":"20","author":"D Cui","year":"2025","unstructured":"Cui D, et al. Natural anti-cancer products: insights from herbal medicine. Chin Med. 2025;20(1):82.","journal-title":"Chin Med"},{"key":"2707_CR198","doi-asserted-by":"publisher","first-page":"113956","DOI":"10.1016\/j.biopha.2022.113956","volume":"156","author":"T Ming","year":"2022","unstructured":"Ming T, et al. Curcumin: An epigenetic regulator and its application in cancer. Biomed Pharmacother. 2022;156:113956.","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"2707_CR199","doi-asserted-by":"publisher","first-page":"e73097","DOI":"10.1371\/journal.pone.0073097","volume":"8","author":"S Venturelli","year":"2013","unstructured":"Venturelli S, et al. Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells. PLoS ONE. 2013;8(8):e73097.","journal-title":"PLoS ONE"},{"issue":"22","key":"2707_CR200","first-page":"7563","volume":"63","author":"MZ Fang","year":"2003","unstructured":"Fang MZ, et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003;63(22):7563\u201370.","journal-title":"Cancer Res"},{"issue":"2","key":"2707_CR201","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1158\/0008-5472.CAN-09-1924","volume":"70","author":"Y Li","year":"2010","unstructured":"Li Y, Li X, Guo B. Chemopreventive agent 3,3\u2019-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases. Cancer Res. 2010;70(2):646\u201354.","journal-title":"Cancer Res"},{"issue":"3","key":"2707_CR202","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1208\/s12248-013-9493-3","volume":"15","author":"TY Wu","year":"2013","unstructured":"Wu TY, et al. Epigenetic modifications of Nrf2 by 3,3\u2019-diindolylmethane in vitro in TRAMP C1 cell line and in vivo TRAMP prostate tumors. Aaps j. 2013;15(3):864\u201374.","journal-title":"Aaps j"},{"issue":"7","key":"2707_CR203","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/nutrit\/nuw010","volume":"74","author":"CA Thomson","year":"2016","unstructured":"Thomson CA, Ho E, Strom MB. Chemopreventive properties of 3,3\u2019-diindolylmethane in breast cancer: evidence from experimental and human studies. Nutr Rev. 2016;74(7):432\u201343.","journal-title":"Nutr Rev"},{"issue":"18","key":"2707_CR204","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1016\/j.febslet.2006.06.092","volume":"580","author":"Y Sun","year":"2006","unstructured":"Sun Y, et al. Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation. FEBS Lett. 2006;580(18):4353\u20136.","journal-title":"FEBS Lett"},{"issue":"10","key":"2707_CR205","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1182\/blood-2007-10-117994","volume":"111","author":"B Sung","year":"2008","unstructured":"Sung B, et al. Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-kappaB-regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-kappaBalpha kinase, leading to potentiation of apoptosis. Blood. 2008;111(10):4880\u201391.","journal-title":"Blood"},{"issue":"1","key":"2707_CR206","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12906-018-2139-3","volume":"18","author":"M Park","year":"2018","unstructured":"Park M, et al. Anacardic acid inhibits pancreatic cancer cell growth, and potentiates chemotherapeutic effect by Chmp1A - ATM - p53 signaling pathway. BMC Complement Altern Med. 2018;18(1):71.","journal-title":"BMC Complement Altern Med"},{"issue":"1","key":"2707_CR207","doi-asserted-by":"publisher","first-page":"9540","DOI":"10.1038\/s41598-024-60395-x","volume":"14","author":"S Nimal","year":"2024","unstructured":"Nimal S, et al. Apigenin and its combination with Vorinostat induces apoptotic-mediated cell death in TNBC by modulating the epigenetic and apoptotic regulators and related miRNAs. Sci Rep. 2024;14(1):9540.","journal-title":"Sci Rep"},{"issue":"2","key":"2707_CR208","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1208\/s12248-016-0016-x","volume":"19","author":"Y Yang","year":"2017","unstructured":"Yang Y, et al. Epigenetic CpG Methylation of the Promoter and Reactivation of the Expression of GSTP1 by Astaxanthin in Human Prostate LNCaP Cells. Aaps j. 2017;19(2):421\u201330.","journal-title":"Aaps j"},{"key":"2707_CR209","doi-asserted-by":"publisher","first-page":"104689","DOI":"10.1016\/j.phrs.2020.104689","volume":"155","author":"I Faraone","year":"2020","unstructured":"Faraone I, et al. Astaxanthin anticancer effects are mediated through multiple molecular mechanisms: A systematic review. Pharmacol Res. 2020;155:104689.","journal-title":"Pharmacol Res"},{"issue":"1","key":"2707_CR210","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40360-021-00473-2","volume":"22","author":"MA Fouad","year":"2021","unstructured":"Fouad MA, et al. Epigenetic immunomodulatory effect of eugenol and astaxanthin on doxorubicin cytotoxicity in hormonal positive breast Cancer cells. BMC Pharmacol Toxicol. 2021;22(1):8.","journal-title":"BMC Pharmacol Toxicol"},{"key":"2707_CR211","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejphar.2014.09.048","volume":"744","author":"SK Saha","year":"2014","unstructured":"Saha SK, Khuda-Bukhsh AR. Berberine alters epigenetic modifications, disrupts microtubule network, and modulates HPV-18 E6-E7 oncoproteins by targeting p53 in cervical cancer cell HeLa: a mechanistic study including molecular docking. Eur J Pharmacol. 2014;744:132\u201346.","journal-title":"Eur J Pharmacol"},{"issue":"50","key":"2707_CR212","doi-asserted-by":"publisher","first-page":"9542","DOI":"10.1021\/acs.jafc.6b04453","volume":"64","author":"A Kalaiarasi","year":"2016","unstructured":"Kalaiarasi A, et al. Plant Isoquinoline Alkaloid Berberine Exhibits Chromatin Remodeling by Modulation of Histone Deacetylase To Induce Growth Arrest and Apoptosis in the A549 Cell Line. J Agric Food Chem. 2016;64(50):9542\u201350.","journal-title":"J Agric Food Chem"},{"issue":"1","key":"2707_CR213","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/jpp\/rgac067","volume":"75","author":"SY Li","year":"2023","unstructured":"Li SY, et al. Berberine inhibits tumour growth in vivo and in vitro through suppressing the lincROR-Wnt\/\u03b2-catenin regulatory axis in colorectal cancer. J Pharm Pharmacol. 2023;75(1):129\u201338.","journal-title":"J Pharm Pharmacol"},{"issue":"8","key":"2707_CR214","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s11010-023-04836-7","volume":"479","author":"X Wang","year":"2024","unstructured":"Wang X, Peng A, Huang C. Suppression of colon cancer growth by berberine mediated by the intestinal microbiota and the suppression of DNA methyltransferases (DNMTs). Mol Cell Biochem. 2024;479(8):2131\u201341.","journal-title":"Mol Cell Biochem"},{"key":"2707_CR215","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3389\/fgene.2019.00514","volume":"10","author":"FU Hassan","year":"2019","unstructured":"Hassan FU, et al. Curcumin as an Alternative Epigenetic Modulator: Mechanism of Action and Potential Effects. Front Genet. 2019;10:514.","journal-title":"Front Genet"},{"key":"2707_CR216","doi-asserted-by":"crossref","unstructured":"Zoi V et al. The Role of Curcumin in Cancer Treatment. Biomedicines, 2021. 9(9).","DOI":"10.3390\/biomedicines9091086"},{"issue":"11","key":"2707_CR217","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.2174\/1389450121666200504080112","volume":"21","author":"L Yang","year":"2020","unstructured":"Yang L, et al. The Epigenetic Modification of Epigallocatechin Gallate (EGCG) on Cancer. Curr Drug Targets. 2020;21(11):1099\u2013104.","journal-title":"Curr Drug Targets"},{"issue":"1","key":"2707_CR218","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12935-023-03161-9","volume":"23","author":"G Wang","year":"2023","unstructured":"Wang G, Wang J, Momeni MR. Epigallocatechin-3-gallate and its nanoformulation in cervical cancer therapy: the role of genes, MicroRNA and DNA methylation patterns. Cancer Cell Int. 2023;23(1):335.","journal-title":"Cancer Cell Int"},{"key":"2707_CR219","doi-asserted-by":"crossref","unstructured":"Kopytko P et al. Garcinol-A Natural Histone Acetyltransferase Inhibitor and New Anti-Cancer Epigenetic Drug. Int J Mol Sci, 2021. 22(6).","DOI":"10.3390\/ijms22062828"},{"key":"2707_CR220","doi-asserted-by":"crossref","unstructured":"Tomasiak P et al. Garcinol and Anacardic Acid, Natural Inhibitors of Histone Acetyltransferases, Inhibit Rhabdomyosarcoma Growth and Proliferation. Molecules, 2023. 28(14).","DOI":"10.3390\/molecules28145292"},{"key":"2707_CR221","doi-asserted-by":"crossref","unstructured":"Pochana G et al. Garcinol as an Epigenetic Modulator: Mechanisms of Anti-Cancer Activity and Therapeutic Potential. Int J Mol Sci, 2025. 26(22).","DOI":"10.3390\/ijms262210917"},{"key":"2707_CR222","doi-asserted-by":"crossref","unstructured":"Fernandes GFS et al. Epigenetic Regulatory Mechanisms Induced by Resveratrol. Nutrients, 2017. 9(11).","DOI":"10.3390\/nu9111201"},{"key":"2707_CR223","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.biocel.2019.05.020","volume":"113","author":"E Izquierdo-Torres","year":"2019","unstructured":"Izquierdo-Torres E, et al. Resveratrol up-regulates ATP2A3 gene expression in breast cancer cell lines through epigenetic mechanisms. Int J Biochem Cell Biol. 2019;113:37\u201347.","journal-title":"Int J Biochem Cell Biol"},{"issue":"5","key":"2707_CR224","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s12282-023-01465-2","volume":"30","author":"T Sakamoto","year":"2023","unstructured":"Sakamoto T, et al. Resveratrol exhibits diverse anti-cancer activities through epigenetic regulation of E-cadherin and p21 in triple-negative breast cancer cells. Breast Cancer. 2023;30(5):727\u201338.","journal-title":"Breast Cancer"},{"issue":"4","key":"2707_CR225","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2217\/epi.11.71","volume":"3","author":"TM Hardy","year":"2011","unstructured":"Hardy TM, Tollefsbol TO. Epigenetic diet: impact on the epigenome and cancer. Epigenomics. 2011;3(4):503\u201318.","journal-title":"Epigenomics"},{"issue":"9","key":"2707_CR226","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1101\/gad.1652908","volume":"22","author":"PA Cloos","year":"2008","unstructured":"Cloos PA, et al. Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev. 2008;22(9):1115\u201340.","journal-title":"Genes Dev"},{"issue":"10","key":"2707_CR227","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1111\/bph.16237","volume":"182","author":"D Dorna","year":"2025","unstructured":"Dorna D, Grabowska A, Paluszczak J. Natural products modulating epigenetic mechanisms by affecting histone methylation\/demethylation: Targeting cancer cells. Br J Pharmacol. 2025;182(10):2137\u201358.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"2707_CR228","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/advances\/nmx011","volume":"9","author":"AL Lopresti","year":"2018","unstructured":"Lopresti AL. The Problem of Curcumin and Its Bioavailability: Could Its Gastrointestinal Influence Contribute to Its Overall Health-Enhancing Effects? Adv Nutr. 2018;9(1):41\u201350.","journal-title":"Adv Nutr"},{"key":"2707_CR229","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2147\/IJN.S443692","volume":"19","author":"Y Lv","year":"2024","unstructured":"Lv Y, et al. Nano-Drug Delivery Systems Based on Natural Products. Int J Nanomed. 2024;19:541\u201369.","journal-title":"Int J Nanomed"},{"key":"2707_CR230","doi-asserted-by":"publisher","first-page":"101963","DOI":"10.1016\/j.mtbio.2025.101963","volume":"33","author":"Y Yan","year":"2025","unstructured":"Yan Y, et al. Advancing cancer therapy: Nanomaterial-based encapsulation strategies for enhanced delivery and efficacy of curcumin. Mater Today Bio. 2025;33:101963.","journal-title":"Mater Today Bio"},{"issue":"3","key":"2707_CR231","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s11095-014-1502-4","volume":"32","author":"HE Hassan","year":"2015","unstructured":"Hassan HE, et al. Curcumin and dimethoxycurcumin induced epigenetic changes in leukemia cells. Pharm Res. 2015;32(3):863\u201375.","journal-title":"Pharm Res"},{"issue":"1","key":"2707_CR232","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41392-023-01528-y","volume":"8","author":"R Liu","year":"2023","unstructured":"Liu R, et al. Methylation across the central dogma in health and diseases: new therapeutic strategies. Signal Transduct Target Ther. 2023;8(1):310.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"2707_CR233","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1074\/jbc.M210256200","volume":"278","author":"F Fuks","year":"2003","unstructured":"Fuks F, et al. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem. 2003;278(6):4035\u201340.","journal-title":"J Biol Chem"},{"key":"2707_CR234","doi-asserted-by":"publisher","first-page":"949095","DOI":"10.3389\/fnmol.2022.949095","volume":"15","author":"J Wang","year":"2022","unstructured":"Wang J, et al. Long Non-coding RNA HOTAIR in Central Nervous System Disorders: New Insights in Pathogenesis, Diagnosis, and Therapeutic Potential. Front Mol Neurosci. 2022;15:949095.","journal-title":"Front Mol Neurosci"},{"issue":"3","key":"2707_CR235","doi-asserted-by":"publisher","first-page":"e41948","DOI":"10.1016\/j.heliyon.2025.e41948","volume":"11","author":"K Ganapathy","year":"2025","unstructured":"Ganapathy K, et al. Reciprocal regulation between DNMT3A\/3B and microRNAs miRs-299-3p\/-30e is a causal factor for the downregulation of microRNAs targeting androgen receptor in prostate cancer. Heliyon. 2025;11(3):e41948.","journal-title":"Heliyon"},{"issue":"4","key":"2707_CR236","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1093\/nar\/gkac080","volume":"50","author":"AN Jones","year":"2022","unstructured":"Jones AN, et al. Structural effects of m6A modification of the Xist A-repeat AUCG tetraloop and its recognition by YTHDC1. Nucleic Acids Res. 2022;50(4):2350\u201362.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2707_CR237","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13148-024-01773-0","volume":"16","author":"X Yin","year":"2024","unstructured":"Yin X, et al. Epigenetic modifications involving ncRNAs in digestive system cancers: focus on histone modification. Clin Epigenetics. 2024;16(1):162.","journal-title":"Clin Epigenetics"},{"issue":"5","key":"2707_CR238","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.trecan.2017.04.004","volume":"3","author":"EN Wainwright","year":"2017","unstructured":"Wainwright EN, Scaffidi P. Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity. Trends Cancer. 2017;3(5):372\u201386.","journal-title":"Trends Cancer"},{"key":"2707_CR239","doi-asserted-by":"crossref","unstructured":"Kumar VE et al. Targeting Epigenetic Modifiers of Tumor Plasticity and Cancer Stem Cell Behavior. Cells, 2022. 11(9).","DOI":"10.3390\/cells11091403"},{"issue":"10","key":"2707_CR240","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1038\/s12276-022-00862-5","volume":"54","author":"S Min","year":"2022","unstructured":"Min S, et al. Transcriptional regulation and chromatin dynamics at DNA double-strand breaks. Exp Mol Med. 2022;54(10):1705\u201312.","journal-title":"Exp Mol Med"},{"key":"2707_CR241","doi-asserted-by":"publisher","first-page":"100090","DOI":"10.1016\/j.pscia.2025.100090","volume":"3","author":"Q Xue","year":"2025","unstructured":"Xue Q, et al. The applications of single-cell multiomics in drug screening. Pharm Sci Adv. 2025;3:100090.","journal-title":"Pharm Sci Adv"},{"key":"2707_CR242","doi-asserted-by":"crossref","unstructured":"Shevade K et al. Simultaneous capture of single cell RNA-seq, ATAC-seq, and CRISPR perturbation enables multiomic screens to identify gene regulatory relationships. Cell Rep Methods, 2025. 5(12).","DOI":"10.1016\/j.crmeth.2025.101222"},{"issue":"12","key":"2707_CR243","doi-asserted-by":"publisher","first-page":"100359","DOI":"10.1016\/j.crmeth.2022.100359","volume":"2","author":"R Gupta","year":"2022","unstructured":"Gupta R, et al. Simulation-based inference of differentiation trajectories from RNA velocity fields. Cell Rep Methods. 2022;2(12):100359.","journal-title":"Cell Rep Methods"},{"issue":"1","key":"2707_CR244","doi-asserted-by":"publisher","first-page":"10048","DOI":"10.1038\/s41467-025-66376-6","volume":"16","author":"Z Wang","year":"2025","unstructured":"Wang Z, et al. Drug-tolerant persister cells in cancer: bridging the gaps between bench and bedside. Nat Commun. 2025;16(1):10048.","journal-title":"Nat Commun"},{"key":"2707_CR245","doi-asserted-by":"publisher","first-page":"216281","DOI":"10.1016\/j.canlet.2023.216281","volume":"567","author":"Y Wang","year":"2023","unstructured":"Wang Y, Zhang X, Wang Z. Cellular barcoding: From developmental tracing to anti-tumor drug discovery. Cancer Lett. 2023;567:216281.","journal-title":"Cancer Lett"},{"key":"2707_CR246","doi-asserted-by":"crossref","unstructured":"Tian Y et al. Epigenomic analysis identifies DTP subpopulation using HOPX to develop targeted therapy resistance in lung adenocarcinoma. iScience, 2025. 28(5).","DOI":"10.1016\/j.isci.2025.112387"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02707-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02707-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02707-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:06:40Z","timestamp":1786536400000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02707-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":246,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2707"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02707-5","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"7 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"193"}}